In a study [24] aimed at identifying novel putative therapeutic targets for SHH-dependent medulloblastomas, CK2 was found as a SHH signaling driver, and its inhibition was shown to decrease the viability of patient-derived cells resistant to SHH inhibitors, in vitro and in murine models. The gene discussed is SHH; the disease is medulloblastoma.